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Objective: We compared contemporary active surveillance protocols based on pathological
outcomes in patients who underwent radical prostatectomy.
Methods: We identified the experimental cohort from prostate cancer patients who underwent
radical prostatectomy between 2001 and 2011, and who met the inclusion criteria of five pub-
lished active surveillance protocols, namely Johns Hopkins Medical Institution, University of
California at San Francisco, Memorial Sloan-Kettering Cancer Center, University of Miami
and Prostate Cancer Research International: Active Surveillance. To compare each protocol,
we evaluated the pathological outcomes and calculated the sensitivity, specificity and accur-
acy for each protocol according to the proportion of organ-confined Gleason 6 disease.
Results: Overall, 376 patients met the inclusion criteria of the active surveillance protocols
with 61, 325, 222, 212 and 206 patients meeting the criteria of the Johns Hopkins Medical
Institution, University of California at San Francisco, Memorial Sloan-Kettering Cancer
Center, University of Miami and Prostate Cancer Research International: Active Surveillance
protocols, respectively. The sensitivity and specificity values of the five protocols, respective-
ly, were 0.199 and 0.882 in Johns Hopkins Medical Institution, 0.855 and 0.124 in University
of California at San Francisco, 0.638 and 0.468 in Memorial Sloan-Kettering Cancer Center,
0.599 and 0.479 in University of Miami, and 0.609 and 0.527 in Prostate Cancer Research
International: Active Surveillance. In terms of both the sensitivity and specificity, Prostate
Cancer Research International: Active Surveillance was the most balanced protocol. In add-
ition, Prostate Cancer Research International: Active Surveillance showed a more accurate
performance for favourable pathological outcomes than the others. However, using the area
under the curve to compare the discriminative ability of each protocol, there were no statistic-
ally significant differences.
Conclusions: The contemporary active surveillance protocols showed similar pathological
characteristics in patients who had undergone radical prostatectomy. However, we concluded
that the Prostate Cancer Research International: Active Surveillance protocol would be most
helpful to Korean populations in choosing candidates for active surveillance considering the
balance between sensitivity and specificity and the accuracy of diagnosis.
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Radical prostatectomy (RP) is a curative treatment method
for localized organ-conﬁned prostate cancer. Therefore,
many urologists perform RP in prostate cancer patients diag-
nosed with clinically localized prostate cancer. Among
patients with clinically localized organ-conﬁned prostate
cancer who underwent RP, we noted that some have very
low-risk prostate cancer with insigniﬁcant tumour character-
istics (1,2). It is well-known that insigniﬁcant prostate cancer
tends to have good oncological outcomes (3). Moreover,
some urologists suggest that insigniﬁcant prostate cancer is
the product of overdiagnosis and that RP is overtreatment for
these patients (4).
Recently, several studies have reported that active surveil-
lance (AS) is a means of managing low-risk prostate cancer
patients and that their own AS protocol is suitable to distin-
guish low-risk prostate cancer patients with insigniﬁcant
prostate cancer (5–10). Several published studies have com-
pared the abilities of individual contemporary AS protocols
in order to determine which protocol is the most efﬁcient
(11–15), but only a few comparisons have been performed
in Asian populations. Among these were studies done by
Goto et al. (15), who reported on the utility of AS protocols
in a Japanese population. However, the small study samples
in these studies limited the results. In the present study, we
compared the ability of each of ﬁve contemporary published
AS protocols to predict organ-conﬁned Gleason 6 prostate
cancer by evaluating the pathological outcomes among pros-
tate cancer patients at our institute.
PATIENTS AND METHODS
We reviewed the records of 2108 prostate cancer patients
who underwent RP performed by one of four surgeons
(K.H.R., B.H.C., S.J.H. and S.C.Y.) between 2001 and 2011
at Yonsei University Hospital, Seoul, Korea. Among them,
we excluded 405 patients who received neo-adjuvant treat-
ment and 41 patients who did not undergo prostate magnetic
resonance imaging (MRI) for the evaluation of clinical
stage. Among the remaining 1662 patients, we identiﬁed
376 patients who met the criteria established by the
contemporary AS protocols with an available pathological
report for the prostate biopsy including all biopsy cores. The
clinical stages of all the prostate cancer patients included in
this study were determined by prostate MRI.
We stratiﬁed patients according to ﬁve published AS pro-
tocols. These ﬁve protocols were from the Johns Hopkins
Medical Institution (JHMI) (5), University of California at
San Francisco (UCSF) (6), Memorial Sloan-Kettering
Cancer Center (MSKCC) (7), University of Miami (UM) (8)
and Prostate Cancer Research International: Active
Surveillance (PRIAS) (9). The criteria for each AS protocol
are shown in Table 1.
Among the study cohort, 170 patients underwent prostate
biopsies at our institute. The pathological results of 206 pros-
tate biopsies performed at external hospitals were reviewed
by an institutional genitourinary pathologist. A minimum of
six cores were examined. Prostate volume (PV) was mea-
sured using transrectal ultrasound. However, we calculated
the PV by multiplying the prostate weight by 0.85 for the 43
patients lacking PV data (16).
We collected the clinicopathologic outcomes including
age, PV, prostate-speciﬁc antigen (PSA) at diagnosis, PSA
density (PSAD), pre-operative Gleason score, clinical stage,
number of prostate biopsy cores, number of positive prostate
biopsy cores, single core involvement, post-operative
Gleason score, pathological stage, extracapsular extension
(ECE), seminal vesicle invasion (SVI), surgical margin
status and biochemical recurrence (BCR). We calculated the
sensitivity and speciﬁcity of each protocol and compared the
balance of each protocol according to the sum of the sensi-
tivity and the speciﬁcity for organ-conﬁned Gleason 6
prostate cancer. And we also compared the diagnostic accur-
acy for organ-conﬁned Gleason 6 prostate cancer.
To compare the pathological outcomes of each protocol,
we used Fisher’s exact test. The actual risk of BCR was
calculated using the Kaplan–Meier method. To compare
the discriminative ability of each protocol, the area under
the receiver operating characteristics curve (AUC) was
calculated. All statistical analyses were performed using
the SAS statistical package (Version 9.1; SAS Institute,
Cary, NC, USA). A P value of 0.05 was considered
statistically signiﬁcant.
Table 1. Active surveillance protocols in recently published literature
Protocol (principal investigator) Gleason score Clinical stage PSA (ng/ml) PSAD No. of positive cores Single core involvement (%)
JHMI 6, no pattern 4 or 5 T1c — 0.15 2 50
UCSF 6, no pattern 4 or 5 T1c-T2 10 — 33 (of at least 6) 50
MSKCC 6 T1c-T2a 10 — 3 50
UM 6 T1c-T2 15 — 2 20
PRIAS 6 T1c-T2 10 0.2 2 —
JHMI, Johns Hopkins Medical Institution; UCSF, University of California at San Francisco; MSKCC, Memorial Sloan-Kettering Cancer Center; UM,
University of Miami; PRIAS, Prostate Cancer Research International: Active Surveillance.





















The baseline characteristics of patients who met the criteria
of each protocol are shown in Table 2. A total of 376 AS
candidates underwent RP with 61, 325, 222, 212 and 206
patients meeting the JHMI, UCSF, MSKCC, UM and PRIAS
criteria, respectively. The mean age was 63.7+ 7.17 years,
the mean PSA was 6.26 ng/ml, and the mean PSAD was
0.18. A total of 202 (53.7%) patients had one positive core.
The percentage of patients having single core involvement
was 18.1%.
In evaluating the pathological specimens, 234 (62.3%)
patients were found to have a post-operative Gleason score
of 6 and 8 (2.1%) patients had post-operative Gleason
scores of 8–10. Gleason upgrading (post-operative Gleason
scores 7–10) was observed in 142 (37.7%) patients. A
primary Gleason score of 4 was noted in 46 (12.2%)
patients, and 5 (1.3%) patients had a Gleason score of
5. Pathological stage T2 was described in 314 (83.5%)
patients, and T3 (upstaging) was observed in 62 (16.5%)
patients. ECE occurred in 59 (15.7%) patients, and SVI oc-
curred in 3 (0.8%) patients. Organ-conﬁned Gleason 6
prostate cancer was found in 207 (55.1%) patients, and 67
(17.8%) patients were characterized by unfavourable disease
features (ECE and/or SVI and/or post-operative Gleason
scores 8–10).
Table 3 shows the pathological outcomes of each protocol.
There were no statistical differences in the distribution of
post-operative Gleason scores, pathological stages, post-
operative upgrading, organ-conﬁned Gleason 6 disease,
unfavourable disease features and BCR rate. A log-rank test
of the Kaplan–Meier survival curves demonstrated no
signiﬁcant difference in overall BCR rate across each
protocol (Fig. 1, log rank P ¼ 0.754). However, the JHMI
protocol showed the lowest sensitivity, and the UCSF protocol
showed the lowest speciﬁcity. The PRIAS protocol had the
best balance between sensitivity and speciﬁcity among
the ﬁve AS protocols. In addition, the PRIAS protocol had the
best diagnostic accuracy for organ-conﬁned Gleason 6 pros-
tate cancer (Table 4).
Comparing the area under the curve for the discriminative
ability of each protocol, the JHMI protocol showed a lower
AUC (57.7%) compared with the other protocols. However,
there was no statistically signiﬁcant difference between the
AS protocols (Table 5 and Fig. 2).
DISCUSSION
One of the recent issues related to prostate cancer is over-
diagnosis and overtreatment. Because of PSA screening, the
increasing incidence of prostate cancer is an ongoing phe-
nomenon in Korea and the rest of Asia as well. The
increased number of diagnoses of clinically localized pros-
tate cancer is remarkable in comparison with the number in
past decades in Korea and RP is the main treatment choice
of these patients in Korea (17). In observing the natural
course of prostate cancer, low-risk prostate cancer patients
have better oncological outcomes than other risk groups. It is
obvious that insigniﬁcant prostate cancer after RP suggests
over-diagnosis and overtreatment. To reduce overtreatment
of these patients, several investigators have developed their
own AS programme.
Recently, long-term follow-up data with AS were reported
from several institutes. Klotz et al. (18) reported that the
10-year survival rate for prostate cancer was 97.2% in their
AS group. They concluded that low-risk prostate cancer has
a low mortality rate; however, more precise identiﬁcation of
AS candidates is needed. Holmstro¨m et al. (19) reported that
there were no statistical differences between the AS cohort
Table 2. Baseline characteristics of the study cohort
No. of patients 376
Age 63.7+ 7.17

















Primary Gleason score 4 46 (12.2)




Extracapsular extension 59 (15.7%)
Seminal vesicle invasion 3 (0.8%)
Positive surgical margin 84 (22.3%)
Upstaging (pT3) 62 (16.5%)
Upgrading (post-operative Gleason score 7–10) 142 (37.7%)
Organ-conﬁned Gleason score 6 disease 207 (55.1%)
Unfavourable disease (ECE, SVI, Gleason score 8–10) 67 (17.8%)
PSA, prostate-speciﬁc antigen; PSAD, PSA density; ECE, extracapsular
extension; SVI, seminal vesicle invasion.




















Table 3. Pathological outcomes of different active surveillance protocols
JHMI UCSF MSKCC UM PRIAS P value
No. of patients 61 325 222 212 206
Post-operative Gleason score
6 43 (70.5%) 202 (62.2%) 147 (66.2%) 143 (67.4%) 138 (67.0%) 0.787
7 16 (26.2%) 117 (36.0%) 71 (31.9%) 64 (30.2%) 63 (30.6%)
8–10 2 (3.3%) 6 (1.8%) 4 (1.9%) 5 (2.4%) 5 (2.4%)
Pathological stage
pT2 56 (91.8%) 268 (82.5%) 189 (85.1%) 177 (83.5%) 179 (86.9%) 0.111
pT3 (upstaging) 5 (8.2%) 57 (17.5%) 33 (14.9%) 35 (16.5%) 21 (10.2%)
Upgrading (post-operative Gleason score 7–10) 18 (29.5%) 123 (37.8%) 75 (33.8%) 69 (32.5%) 68 (33.0%) 0.592
Organ-conﬁned Gleason 6 disease 41 (67.2%) 177 (54.5%) 132 (59.5%) 124 (58.5%) 126 (61.2%) 0.218
Unfavourable diseasea 7 (11.5%) 59 (18.2%) 36 (16.2%) 39 (18.3%) 29 (14.0%) 0.548
Biochemical recurrence rate 2 (3.3%) 24 (7.4%) 13 (5.9%) 16 (7.5%) 12 (5.8%) 0.763
aExtracapsular extension and/or seminal vesicle invasion and/or Gleason scores 8–10.
Figure 1. Comparison of Kaplan–Meier biochemical recurrence-free sur-
vival curves after radical prostatectomy across the active surveillance proto-
cols (JHMI, Johns Hopkins Medical Institution; UCSF, University of
California at San Francisco; MSKCC, Memorial Sloan-Kettering Cancer
Center; UM, University of Miami; PRIAS, Prostate Cancer Research
International: Active Surveillance).
Table 4. Comparison of the diagnostic accuracy of the active surveillance
protocols for organ-conﬁned Gleason score 6 disease
JHMI UCSF MSKCC UM PRIAS
Sensitivity 0.199 0.855 0.638 0.599 0.609
Speciﬁcity 0.882 0.124 0.468 0.479 0.527
Positive predictive value 0.672 0.544 0.594 0.584 0.612
Negative predictive value 0.190 0.156 0.201 0.170 0.224
Accuracy 0.505 0.525 0.558 0.546 0.569
Table 5. Comparison of receiver operating characteristic curves of the
active surveillance protocols for organ-conﬁned Gleason score 6 disease
P value
AUC 95% CI JHMI UCSF MSKCC UM
JHMI 0.577 0.426–0.728 — — — —
UCSF 0.621 0.590–0.652 0.600 — — —
MSKCC 0.612 0.573–0.651 0.687 0.856 — —
UM 0.613 0.573–03653 0.681 0.872 0.987 —
PRIAS 0.615 0.574–0.656 0.665 0.907 0.957 0.970
Figure 2. Comparison of receiver operating characteristic curves of the
active surveillance protocols for organ-conﬁned Gleason 6 disease.




















and the low-risk prostate cancer cohort of patients who were
treated with RP and radiotherapy during a 10-year follow-up
period (19). Recently, Suardi et al. (20) concluded that an
AS programme is signiﬁcantly better for managing prostate
cancer patients younger than 70 years. Drawing from these
studies, we suggest that AS is a suitable option for reducing
overtreatment in low-risk prostate cancer patients.
In the present study, we compared ﬁve contemporary AS
protocols from the following institutions: the JHMI (5),
UCSF (6), MSKCC (7), UM (8) and PRIAS (9). Another AS
protocol used in an Asian cohort also exists; it was devel-
oped by the KaKehi et al. (10) research team in Japan.
However, this AS protocol includes intermediate-risk pros-
tate cancer patients with a PSA level of ,20 ng/ml as AS
candidates. Therefore, despite the fact that this AS protocol
was developed in an Asian population, we excluded it from
the present study because we chose to focus speciﬁcally on
low-risk prostate cancer patients.
When comparing the characteristics of each protocol’s cri-
teria, it is evident that the JHMI protocol is most stringent.
The JHMI protocol is limited to patients with clinical stage
T1c disease and PSAD 0.15 ng/ml. In contrast, the UCSF
protocol has the most lenient inclusion criteria among the
protocols. This protocol has no limitations regarding the
number of positive cores. According to their criteria, all
patients with 33% positive cores among any number of total
cores could be AS candidates. These conditions were also
applied to the present study. We identiﬁed only 61 patients
(16.2% of 376) who fulﬁlled the JHMI criteria, while 325
(86.4% of 376) fulﬁlled the UCSF criteria. The PRIAS,
MSKCC and UM protocols had similar numbers of AS can-
didates among the prostate cancer patients who underwent
RP at our institute despite slight differences in their individ-
ual criteria.
Although there are some differences in the details of each
protocol, the overarching aims of all AS protocols are
similar: to identify prostate cancer patients with indolent
tumours and to reduce aggressive treatment in these patients.
When we compared the pathological outcomes of AS candi-
dates who underwent RP according to the criteria of different
AS protocols, we found that all the ﬁve AS protocols ful-
ﬁlled these aims sufﬁciently. The discriminative performance
of each protocol and the BCR survival rate of AS candidates
were not statistically different (Figs. 1 and 2). We deter-
mined that selection of AS candidates based on the JHMI
protocol resulted in the lowest frequencies of upstaging, up-
grading and unfavourable disease. The JHMI protocol
showed the best ability to identify organ-conﬁned prostate
cancer with a Gleason score of 6 (Table 3). However, only
61 men beneﬁtted from the programme because of the strin-
gent JHMI criteria. When we examined the pathological out-
comes of the 315 patients in other AS protocols, we found
that 165 (52%) had organ-conﬁned Gleason 6 prostate
cancer, while 60 (19%) had unfavourable disease features
with a Gleason score of 8–10 and/or ECE and/or SVI. This
means that these 165 men lost the opportunity to undergo
AS, and the disease would have progressed in 60 of the
patients with unfavourable disease had they undergone AS.
We thought that the losses outweighed the gains in the JHMI
protocol when considering the aim of the AS protocol. By
contrast, the UCSF protocol showed the opposite results
compared with the JHMI protocol. Because of the more
lenient inclusion criteria, 325 men could have been AS can-
didates based on the UCSF protocol. However, the patho-
logical outcomes were generally not good in comparison
with the results from the other four AS protocols. Even
though more prostate cancer patients had the chance to use
the AS program using the UCSF protocol, urologists would
lose the chance for proper timing and decision-making for
patients with unfavorable disease if they were included in
the UCSF protocol. In other words, the JHMI protocol and
the UCSF protocol did not perform well with regard to the
balance between the sensitivity and the speciﬁcity (Table 4).
The remaining three AS protocols resulted in the selection
of a similar number of AS candidates and the balance
between the sensitivity and speciﬁcity of the protocols were
also quite similar. In terms of pathological outcomes and the
balance between sensitivity and speciﬁcity among these
three AS protocols, the PRIAS protocol performed the best
in selecting AS candidates. In addition, the PRIAS protocol
had the highest diagnostic accuracy for organ-conﬁned
Gleason 6 prostate cancer. This result is similar to that
from the evaluation of a Japanese cohort (15).
On the basis of our ﬁndings, we consider the PRIAS
protocol the most balanced and accurate AS protocol for
Korean populations because of the background of its devel-
opment. AS protocols from JHMI, UCSF, MSKCC and UM
were generated on the basis of the data from the individual
institutions. However, the PRIAS protocol was developed for
an international prospective study of AS, although it origi-
nated from the Randomized Study of Screening for Prostate
Cancer (ERSPC) and was initiated in the Erasmus MC in the
Netherlands (21). This protocol’s criteria were developed
with consideration for cultural and genetic background. The
speciﬁc difference from other AS protocols is that the
PRIAS does not include single core involvement data. Van
den Bergh et al. (21) explained that the single core involve-
ment information was excluded because the use of each spe-
ciﬁc core in determining the percentage of cancer
involvement is not a currently standard procedure at all path-
ology centrer. This decision rendered the unintended and co-
incidental result that use of the PRIAS protocol has better
outcomes than the other protocols. Because there is no con-
sensus on the predictability of the prostate biopsy proﬁle
using Western cohorts, the question remains as to whether or
not it could be applied to Asian cohorts.
Recently, Choi et al. reported the predictors for insigniﬁ-
cant prostate cancer after RP in a Korean sample (22). They
reviewed the pathological outcomes of 1471 men who were
treated at multiple institutions in Korea. They concluded that
insigniﬁcant prostate cancer in Koreans had the following
characteristics: mean preoperative PSA, 5.3 ng/ml; mean




















PSAD, 0.21; mean number of positive cores, 1.6; average
percentage of core involvement, 0.13% and maximum per-
centage of any single core, 16.8% (Table 6). These condi-
tions are consistent with the PRIAS protocol. In contrast, the
criteria for the MSKCC protocol and the UM protocol mea-
sured similar characteristics, but evaluated signiﬁcant pros-
tate cancer rather than insigniﬁcant prostate cancer in
Korean populations. Therefore, these studies support the ar-
gument that the PRIAS protocol is an appropriate protocol
for Korean patients.
It is possible to develop a novel AS protocol for Korean
populations to predict insigniﬁcant prostate cancer using a
Korean database. However, this is beyond the scope of the
present study. Nevertheless, we believe that a more accurate
and balanced AS protocol for Asian populations is needed.
We found that the proportion of patients with organ-
conﬁned Gleason 6 prostate cancer is lower in Korean
populations than in Western populations (11). There is a dif-
ference in incidence of about 13–16% between populations
according to the results of Korean and Western studies
using each of the AS protocols. We found this phenomenon
not only in the present study, but also in another study of a
Korean cohort (23,24). Despite the fact that the authors
used the JHMI protocol (Epstein criteria), which has the
most stringent characteristics, they indicated that Korean
patients seem to have a greater incidence of prostate cancer
with unfavourable pathological features than do Western
patients. On the basis of this assertion, we debated whether
or not a comparison of the ability of each published AS
protocol has signiﬁcant meaning. This is because the per-
formance of the AS protocols generally differs between
Western and Asian cohorts. However, considering that an
AS protocol optimized for Asian cohorts does not yet exist,
a validation of the existing AS protocols would be import-
ant both for urologists and for patients because AS will
soon become one of the main treatment choices in Asian
populations (25).
A main limitation of the present study is that we simply
examined the pathological outcomes in prostate cancer
patients who underwent RP. Recently, many studies have
reported the oncological outcomes of the AS programme in
real practice and the pathological outcomes of prostate
cancer patients who underwent RP after AS because of sus-
picious disease progression. Therefore, some readers could
regard our ﬁndings as outdated. However, considering the
fact that there have not yet been studies comparing published
AS protocols using Asian cohorts, our results might be
helpful in guiding urologists’ selection of the proper AS
protocol to use for low-risk prostate cancer patients, particu-
larly AS candidates.
In conclusion, the present study shows that RP specimens
evaluated according to contemporary AS protocols have
quite similar pathological characteristics. Nevertheless, we
conclude that among the ﬁve AS protocols studied, the
PRIAS protocol would be most helpful in choosing the ap-
propriate patients for AS when taking into consideration the
balance between sensitivity and speciﬁcity, diagnostic accur-
acy and characteristics of Korean patients with insigniﬁcant
prostate cancer. We believe that the development of an opti-
mized AS protocol for Asian populations is the next logical
step moving forward.
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